Assessing the Efficacy and Acceptability of Two Missed Period Pills Regimens

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

286

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Pregnancy EarlyPregnancy Related

Interventions

DRUG

Levonorgestrel

Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel

DRUG

Mifepristone

Participants in both groups will receive one tablet of 200 mg mifepristone

All Listed Sponsors

collaborator

Cuidado Integral de la Mujer, Gineclinic, S.C.

UNKNOWN

collaborator

Servicios de Salud Medieg, A. C

UNKNOWN

lead

Gynuity Health Projects

OTHER

NCT06492889 - Assessing the Efficacy and Acceptability of Two Missed Period Pills Regimens | Biotech Hunter | Biotech Hunter